Evidence map›Paper›PMID 38265474›Full record

ArticleArchives of toxicology2024

Utility of in vivo metabolomics to support read-across for UVCB substances under REACH.

H Kamp, N Aygun Kocabas, F Faulhammer, N Synhaeve, E Rushton, B Flick, V Giri, S Sperber, L G Higgins, M G Penman and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Archives of toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

H KampBASF Metabolome Solutions GmbH, Berlin, Germany.
N Aygun KocabasTotalEnergies Refining & Chemicals, Seneffe, Belgium.
F FaulhammerBASF SE, Ludwigshafen, Germany.
N SynhaeveExxonMobil, Machelen, Belgium.
E RushtonLyondellBasell, Rotterdam, The Netherlands.
B FlickBASF SE, Ludwigshafen, Germany.
V GiriBASF SE, Ludwigshafen, Germany.
S SperberBASF SE, Ludwigshafen, Germany.
L G HigginsLOA C/O Penman Consulting Ltd, Brussels, Belgium.
M G PenmanLOA C/O Penman Consulting Ltd, Brussels, Belgium.
B van RavenzwaayEnvironmental Sciences Consulting, Altrip, Germany. demou@outlook.de.ORCID 0000-0002-4264-9217
M RooseboomShell Global Solution International B.V, The Hague, The Netherlands.
BASF (Germany) · DEBH Consulting (Ireland) · IEBiobyte Solutions (Germany) · DEShell (Netherlands) · NLTotal (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Structure-based grouping of chemicals for targeted testing and read-across is an efficient way to reduce resources and animal usage. For substances of unknown or variable composition, complex reaction products, or biological materials (UVCBs), structure-based grouping is virtually impossible. Biology-based approaches such as metabolomics could provide a solution. Here, 15 steam-cracked distillates, registered in the EU through the Lower Olefins Aromatics Reach Consortium (LOA), as well as six of the major substance constituents, were tested in a 14-day rat oral gavage study, in line with the fundamental elements of the OECD 407 guideline, in combination with plasma metabolomics. Beyond signs of clinical toxicity, reduced body weight (gain), and food consumption, pathological investigations demonstrated the liver, thyroid, kidneys (males only), and hematological system to be the target organs. These targets were confirmed by metabolome pattern recognition, with no additional targets being identified. While classical toxicological parameters did not allow for a clear distinction between the substances, univariate and multivariate statistical analysis of the respective metabolomes allowed for the identification of several subclusters of biologically most similar substances. These groups were partly associated with the dominant (> 50%) constituents of these UVCBs, i.e., indene and dicyclopentadiene. Despite minor differences in clustering results based on the two statistical analyses, a proposal can be made for the grouping of these UVCBs. Both analyses correctly clustered the chemically most similar compounds, increasing the confidence that this biological approach may provide a solution for the grouping of UVCBs.

Indexed as

MetabolomeMetabolomicsAnimalsKidneyLiverMaleRatsThyroid GlandChemical groupingMetabolomicsNew approach methodologies (NAMs)REACHRead-acrossUVCB

Identifiers

PMID38265474
PMCPMC10861390
OpenAlexW4391169093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.